NYSE: ABTAbbott Laboratories Stock
$124.65-0.48 (-0.38%)
Updated Sep 22, 2021
ABT Price
$124.65
Fair Value Price
N/A
Market Cap
$220.98B
52 Week Low
$100.34
52 Week High
$129.70
P/E
34.92x
P/B
6.49x
P/S
5.13x
PEG
2.71x
Dividend Yield
1.37%
Revenue
$40.23B
Earnings
$6.38B
Gross Margin
55.7%
Operating Margin
19.25%
Profit Margin
15.8%
Debt to Equity
1.15
Operating Cash Flow
$11B
Beta
0.89
Next Earnings
Oct 19, 2021
Ex-Dividend
Oct 14, 2021
Next Dividend
Nov 15, 2021
Zen Score
High
Medium
Low
42
Industry average
Reasons for this score
ABT ($124.65) is trading below its intrinsic value of $211.01, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
ABT is good value based on its earnings relative to its share price (34.92x), compared to the US market average -10.34x)
Valuation
ABT is good value based on its earnings relative to its share price (34.92x), compared to the US Medical Devices industry average (52.41x)
Valuation
ABT News
Valuation
ABT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
34.92x
Industry
52.41x
Market
-10.34x
ABT is good value based on its earnings relative to its share price (34.92x), compared to the US market average -10.34x)
Valuation
ABT is good value based on its earnings relative to its share price (34.92x), compared to the US Medical Devices industry average (52.41x)
Valuation
ABT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.49x
Industry
5.32x
ABT is poor value based on its book value relative to its share price (6.49x), compared to the US Medical Devices industry average (5.32x)
Valuation
ABT price to earnings growth (PEG)
For valuing profitable companies with growth potential
ABT is poor value relative to its rate of earnings growth, measured by PEG ratio (2.71x)
Valuation
ABT's financial health
Profit margin
Revenue
$10.2B
Net Income
$1.2B
Profit Margin
11.6%
ABT's Earnings (EBIT) of $7.75B can safely cover interest payments on company debt ($18.50B)
Financials
ABT's profit margin has increased (+5.9%) in the last year from (9.9%) to (15.8%)
Financials
Assets to liabilities
Assets
$73.3B
Liabilities
$39.2B
Debt to equity
0.54
ABT's short-term assets ($22.63B) exceed its short-term liabilities ($12.61B)
Financials
ABT's long-term liabilities ($26.63B) exceed its short-term assets ($22.63B)
Financials
ABT's debt has increased relative to shareholder equity (1.15), over the past 5 years ago (0.92)
Financials
ABT's debt to equity ratio (1.15) is considered high
Financials
Cash flow
Operating
$2.1B
Investing
-$264.0M
Financing
-$1.3B
ABT's operating cash flow ($10.63B) is sufficient to service the company's debt ($18.50B)
Financials
Abbott Laboratories Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.